Markets:

Overview

News

Currencies

International

Treasuries

Pharmather Holdings Ltd (OP:PHRRF)

0.0430 +0.0020 (+4.88%)

Delayed Quote Updated: 10:55 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pharmather Holdings Ltd

< Previous 1 2 3 4 5 Next >

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

February 07, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics ↗

February 06, 2023

Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically...

Via Benzinga

MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations ↗

February 06, 2023

Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve

Via Benzinga

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

February 06, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch ↗

February 03, 2023

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.

Via Benzinga

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

February 02, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

February 01, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗

January 25, 2023

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

Via Benzinga

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News ↗

January 21, 2023

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for...

Via Benzinga

Psychedelics Market Could Reach $12B By 2029, Says New Report ↗

January 19, 2023

A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before...

Via Benzinga

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

January 18, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products ↗

January 11, 2023

Two psychedelics companies have shared their updates and key milestones to be reached this 2023.

Via Benzinga

PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

January 11, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status ↗

December 15, 2022

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.

Via Benzinga

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

December 15, 2022

PharmaTher’s 4th FDA orphan drug designation for ketamine

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience

November 14, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder ↗

November 01, 2022

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU)

Via Benzinga

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

November 01, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It ↗

October 05, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine

Via Benzinga

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

October 05, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Provides Business Highlights And Releases Audited Annual Financials ↗

September 29, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.

Via Benzinga

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

September 29, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease ↗

September 17, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced...

Via Benzinga

Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies ↗

September 07, 2022

PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and...

Via Benzinga

PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment ↗

July 13, 2022

Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S.

Via Benzinga

PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing ↗

June 29, 2022

Ketamine-producer PharmaTher Holdings Ltd. (OTCQB: PHRRF) has successfully completed research evaluating its patented hydrogel-forming microneedle patch, PHARMAPATCH, to deliver ketamine and KETABET...

Via Benzinga

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry ↗

June 02, 2022

In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its...

Via Benzinga

More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO ↗

May 26, 2022

PharmaTher Holdings Ltd. (OTC: PHRRF) continues on its path to becoming the leader in specialty ketamine products.

Via Benzinga

Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs ↗

May 10, 2022

Psychedelics policy action took center stage this week.

Via Benzinga

Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process ↗

May 05, 2022

The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.